FXYD5 and neoplasm: Analysis of The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC, v32) dataset further confirmed elevated FXYD5 expression across tumor stages, and its association with reduced overall survival (Fig. 1d, e).